• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CONMED Corporation Announces First Quarter 2025 Financial Results

    4/30/25 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email

    CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025.

    First Quarter 2025 Highlights

    • Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency.
    • Domestic revenue increased 4.2% year-over-year.
    • International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency.
    • Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024.
    • Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024.

    "We had a good start to 2025, which positions us well to achieve our full-year guidance," commented Patrick J. Beyer, CONMED's President and Chief Executive Officer. "I am proud of our team's dedication to strengthening our operations in order to better support our key growth platforms and drive long-term shareholder value."

    2025 Outlook

    Based on current foreign currency exchange rates, the Company now expects revenue currency headwinds of approximately 50 to 70 basis points, compared to 100 to 120 basis points previously. As a result of the Company's updated foreign currency expectations and its first quarter performance, full-year reported revenue is now expected to be between $1.350 billion and $1.378 billion, compared to the prior guidance range of between $1.344 billion and $1.372 billion.

    Primarily as a result of these same updated foreign currency expectations and its first quarter performance, the Company now expects full-year adjusted diluted net earnings per share(2) in the range of $4.45 to $4.60, compared to its prior range of $4.25 to $4.40.

    This updated guidance does not include the effects of recent tariff announcements, which the Company estimates would result in a negative impact to EPS of approximately $0.14 in the second half of 2025.

    Supplemental Financial Disclosures

    (1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

    (2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

    Conference Call

    The Company's management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2025 results.

    To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

    This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

    Consolidated Condensed Statements of Income

    (in thousands except per share amounts, unaudited)

     

     

     

     

     

     

     

    Three Months Ended

     

     

    March 31,

     

     

    2025

     

    2024

     

     

     

     

     

    Net sales

     

    $

    321,256

     

    $

    312,273

    Cost of sales

     

     

    143,504

     

     

    140,308

    Gross profit

     

     

    177,752

     

     

    171,965

    % of sales

     

     

    55.3%

     

     

    55.1%

    Selling & administrative expense

     

     

    148,847

     

     

    123,358

    Research & development expense

     

     

    12,947

     

     

    13,594

    Income from operations

     

     

    15,958

     

     

    35,013

    % of sales

     

     

    5.0%

     

     

    11.2%

    Interest expense

     

     

    8,286

     

     

    9,594

    Income before income taxes

     

     

    7,672

     

     

    25,419

    Provision for income taxes

     

     

    1,636

     

     

    5,710

    Net income

     

    $

    6,036

     

    $

    19,709

     

     

     

     

     

    Basic EPS

     

    $

    0.19

     

    $

    0.64

    Diluted EPS

     

     

    0.19

     

     

    0.63

     

     

     

     

     

    Basic shares

     

     

    30,973

     

     

    30,780

    Diluted shares

     

     

    31,151

     

     

    31,272

     

     Sales Summary

    (in millions, unaudited)

     

    Three Months Ended March 31,

    % Change

    Domestic

    International

    2025

    2024

    As Reported

    Impact of Foreign Currency

    Constant Currency

     

    As Reported

    As Reported

    Impact of Foreign Currency

    Constant Currency

    Orthopedic Surgery

    $

    138.3

    $

    134.9

    2.5%

    1.4%

    3.9%

    -2.1%

    5.6%

    2.3%

    7.9%

    General Surgery

     

    183.0

     

    177.4

    3.2%

    0.6%

    3.8%

    6.9%

    -5.2%

    1.9%

    -3.3%

    $

    321.3

    $

    312.3

    2.9%

    0.9%

    3.8%

    4.2%

    1.2%

    2.2%

    3.4%

     

    Single-use Products

    $

    276.3

    $

    264.7

    4.4%

    1.0%

    5.4%

    6.2%

    1.9%

    2.3%

    4.2%

    Capital Products

     

    45.0

     

    47.6

    -5.6%

    0.9%

    -4.7%

    -9.5%

    -2.0%

    1.7%

    -0.3%

    $

    321.3

    $

    312.3

    2.9%

    0.9%

    3.8%

    4.2%

    1.2%

    2.2%

    3.4%

     

    Domestic

    $

    183.8

    $

    176.4

    4.2%

    0.0%

    4.2%

    International

     

    137.5

     

    135.9

    1.2%

    2.2%

    3.4%

    $

    321.3

    $

    312.3

    2.9%

    0.9%

    3.8%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Reconciliation of Reported Net Income to Adjusted Net Income

    (in thousands, except per share amounts, unaudited)

     

    Three Months Ended March 31, 2025

    Gross Profit

    Selling & Administrative Expense

    Operating Income

    Interest

    Expense

    Tax

    Expense

    Effective Tax Rate

    Net Income

    Diluted EPS

    As reported

    $

    177,752

    $

    148,847

    $

    15,958

    $

    8,286

    $

    1,636

    21.3%

    $

    6,036

    $

    0.19

    % of sales

     

    55.3%

     

    46.3%

     

    5.0%

    Executive transition costs(1)

     

    -

     

    (12,165)

     

    12,165

     

    -

     

    2,812

     

    9,353

    Contingent consideration fair value adjustments(2)

     

    -

     

    (3,962)

     

    3,962

     

    -

     

    916

     

     

    3,046

     

    Operational consulting fees(3)

     

    3,410

     

    (490)

     

    3,900

     

    -

     

    901

     

     

    2,999

     

    Legal matters(4)

     

    -

     

    (1,037)

     

    1,037

     

    -

     

    240

     

     

    797

     

    Gain on sale of product line(5)

     

    -

     

    354

     

    (354)

     

    -

     

    (82)

     

    (272)

    $

    181,162

    $

    131,547

    $

    36,668

    $

    8,286

    $

    6,423

     

    $

    21,959

    Adjusted gross profit %

     

    56.4%

    Amortization(6)

    $

    1,500

     

    (7,172)

     

    8,672

     

    (1,443)

     

    2,455

     

    7,660

    As adjusted

    $

    124,375

    $

    45,340

    $

    6,843

    $

    8,878

    23.1%

    $

    29,619

    $

    0.95

    % of sales

     

     

    38.7%

     

    14.1%

     

     

    Three Months Ended March 31, 2024

    Gross Profit

    Selling & Administrative Expense

    Operating Income

    Interest

    Expense

    Tax

    Expense

    Effective Tax Rate

    Net Income

    Diluted EPS

    As reported

    $

    171,965

    $

    123,358

    $

    35,013

    $

    9,594

    $

    5,710

    22.5%

    $

    19,709

    $

    0.63

    % of sales

     

    55.1%

     

    39.5%

     

    11.2%

    Contingent consideration fair value adjustments(2)

     

    -

     

    6,545

     

    (6,545)

     

    -

     

    (940)

     

     

    (5,605)

     

    Legal matters(4)

     

    -

     

    (1,337)

     

    1,337

     

    -

     

    192

     

     

    1,145

     

    Restructuring and related costs(7)

     

    235

     

    (1,539)

     

    1,774

     

    -

     

    255

     

     

    1,519

     

    Asset impairment costs(8)

     

    1,414

     

    -

     

    1,414

     

    -

     

    203

     

     

    1,211

     

    Termination of distributor agreement(9)

     

    -

     

    970

     

    (970)

     

    -

     

    (139)

     

    (831)

    $

    173,614

    $

    127,997

    $

    32,023

    $

    9,594

    $

    5,281

    $

    17,148

    Adjusted gross profit %

     

    55.6%

    Amortization(6)

    $

    1,500

     

    (7,152)

     

    8,652

     

    (1,407)

     

    2,444

     

    7,615

    As adjusted

    $

    120,845

    $

    40,675

    $

    8,187

    $

    7,725

    23.8%

    $

    24,763

    $

    0.79

    % of sales

     

     

    38.7%

     

    13.0%

     

     

     

     

     

     

     

     

     

    (1) In 2025, the Company incurred cash and stock-based compensation costs related to advisory services provided by our former Chief Executive Officer.

    (2) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration.

    (3) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred costs related to consultants which are included in selling & administrative expense.

    (4) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams.

    (5) In 2025, the Company recognized a gain on the sale of a product line.

    (6) Includes amortization of intangible assets and deferred financing fees.

    (7) In 2024, the Company incurred severance costs related to the elimination of certain positions.

    (8) In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line.

    (9) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement.

     
    Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA

    (in thousands, unaudited)

     

     

    Three Months Ended

     

    March 31,

     

    2025

     

    2024

     

     

     

     

    Net income

    $

    6,036

     

    $

    19,709

    Provision for income taxes

     

    1,636

     

     

    5,710

    Interest expense

     

    8,286

     

     

    9,594

    Depreciation

     

    4,235

     

     

    4,046

    Amortization

     

    14,018

     

     

    13,992

    EBITDA

    $

    34,211

     

    $

    53,051

     

     

     

     

    Stock-based compensation

     

    6,381

     

     

    6,240

    Executive transition costs

     

    12,165

     

     

    -

    Contingent consideration fair value adjustments

     

    3,962

     

     

    (6,545)

    Operational consulting fees

     

    3,900

     

     

    -

    Legal matters

     

    1,037

     

     

    1,337

    Gain on sale of product line

     

    (354)

     

     

    -

    Restructuring and related costs

     

    -

     

     

    1,774

    Asset impairment costs

     

    -

     

     

    1,414

    Termination of distributor agreement

     

    -

     

     

    (970)

    Adjusted EBITDA

    $

    61,302

     

    $

    56,301

     

     

     

     

     

     

     

     

    EBITDA Margin

     

     

     

    EBITDA

     

    10.6%

     

     

    17.0%

    Adjusted EBITDA

     

    19.1%

     

    18.0%

    About CONMED Corporation

    CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

    Forward-Looking Statements

    This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

    Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

    The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company's underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

    Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

    Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

    We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430261812/en/

    CONMED Corporation

    Todd W. Garner

    Chief Financial Officer

    727-214-2975

    [email protected]

    Get the next $CNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    3/2/2022$155.00Neutral
    BofA Securities
    More analyst ratings

    $CNMD
    Financials

    Live finance-specific insights

    See more
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t

      4/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology

    $CNMD
    SEC Filings

    See more
    • CONMED Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - CONMED Corp (0000816956) (Filer)

      5/21/25 4:03:57 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:13:56 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:12:35 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/13/24 4:22:22 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/12/24 12:53:28 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      2/13/24 5:02:29 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Stifel with a new price target

      Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

      4/28/25 8:32:52 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Analyst with a new price target

      Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

      2/6/25 7:05:01 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Needham reiterated coverage on CONMED with a new price target

      Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously

      2/1/24 8:15:04 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Workman John L exercised 479 shares at a strike of $59.84, increasing direct ownership by 2% to 20,891 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/21/25 4:25:37 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by VP GM International Epinette Stephan

      4 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:59:45 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Epinette Stephan claimed ownership of 15,510 shares (SEC Form 3)

      3 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:57:36 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/14/24 3:37:54 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/10/24 5:29:04 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/8/24 4:20:48 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care